BIOLOGICAL RESPONSE MODIFIERS FOR THE TREATMENT OF SUBJECTS WITH UNDERPERFORMING IMMUNE SYSTEMS AND COMPOSITIONS THEREOF

In the present invention, the cyclic-di-nucleotides or their compositions are used as biological response modifiers to improve the immune response of subject with underperforming immune systems with low/non-responsiveness to vaccine antigens or underperforming immune response to pathogens. The formu...

Full description

Saved in:
Bibliographic Details
Main Authors Aguilar Rubido, Julio Cesar, Freyre Almeida, Freya Milagros, Ebensen, Thomas, Schulze, Kai, Guillen Nieto, Gerardo Enrique, Trittel, Stephanie, Guzmán, Carlos A, Riese, Peggy
Format Patent
LanguageEnglish
French
German
Published 02.10.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In the present invention, the cyclic-di-nucleotides or their compositions are used as biological response modifiers to improve the immune response of subject with underperforming immune systems with low/non-responsiveness to vaccine antigens or underperforming immune response to pathogens. The formulations of the present invention are capable of modifying the biological response in the way of abrogating the non-responsiveness resulting in the development of a high avidity immune response preventing the disease caused by infectious agents, in particular from viruses, with the capacity to evade the mechanisms of immune surveillance and consequently suppress the induction of a high avidity and effective adaptive response. The present invention also comprises the formulations of cyclic di-nucleotides, which may be administered alone, in combination with other biological response modifiers or in vaccine formulations with antigens. The proposed invention also includes the method of preventing or treating acute respiratory infections, preventing the severity of the disease and blocking transmission by inducing an immune response at the entry site (nasopharyngeal mucosa), preventing or reducing person-to-person pathogen/virus transmission in pre-emptive vaccine formulations as well as in formulations used for pre-/post exposure prophylaxis of acute respiratory infections.
Bibliography:Application Number: EP20230164382